0000914475-24-000056.txt : 20240214 0000914475-24-000056.hdr.sgml : 20240214 20240214171701 ACCESSION NUMBER: 0000914475-24-000056 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240213 FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GORMAN KEVIN CHARLES CENTRAL INDEX KEY: 0001201096 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 24640584 MAIL ADDRESS: STREET 1: 12790 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 wk-form4_1707948998.xml FORM 4 X0508 4 2024-02-13 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001201096 GORMAN KEVIN CHARLES 12780 EL CAMINO REAL SAN DIEGO CA 92130 1 1 0 0 Chief Executive Officer 0 Common Stock 2024-02-13 4 M 0 2778 35.99 A 509740 D Common Stock 2024-02-13 4 M 0 2312 43.24 A 512052 D Incentive Stock Option 35.99 2024-02-13 4 M 0 2778 35.99 D 2026-02-05 Common Stock 2778 0 D Incentive Stock Option 43.24 2024-02-13 4 M 0 2312 43.24 D 2027-02-06 Common Stock 2312 0 D This transaction involved a cash exercise of a stock option without a subsequent sale of the underlying shares of common stock. 491,365 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. /s/ Darin Lippoldt, Attorney-in-Fact 2024-02-14